USD 0.52
(4.1%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 651 Thousand USD | -63.24% |
2022 | 1.77 Million USD | -37.15% |
2021 | 2.81 Million USD | -47.97% |
2020 | 5.41 Million USD | 136.61% |
2019 | 2.28 Million USD | 6.42% |
2018 | 2.15 Million USD | -73.1% |
2017 | 7.99 Million USD | -53.94% |
2016 | 17.35 Million USD | -9.89% |
2015 | 19.26 Million USD | 269.24% |
2014 | 5.21 Million USD | -82.32% |
2013 | 29.5 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | -100.0% |
2024 Q2 | - USD | 0.0% |
2023 Q2 | 253 Thousand USD | 0.0% |
2023 Q1 | - USD | -100.0% |
2023 Q3 | 117 Thousand USD | -53.75% |
2023 Q4 | 281 Thousand USD | 140.17% |
2023 FY | 651 Thousand USD | -63.24% |
2022 Q2 | 570 Thousand USD | 28.96% |
2022 Q1 | 442 Thousand USD | 22000.0% |
2022 FY | 1.77 Million USD | -37.15% |
2022 Q4 | 252 Thousand USD | -50.3% |
2022 Q3 | 507 Thousand USD | -11.05% |
2021 Q2 | 443 Thousand USD | -13.31% |
2021 Q1 | 511 Thousand USD | -30.76% |
2021 FY | 2.81 Million USD | -47.97% |
2021 Q4 | 2000.00 USD | -99.89% |
2021 Q3 | 1.86 Million USD | 320.32% |
2020 Q1 | 386 Thousand USD | -18.74% |
2020 FY | 5.41 Million USD | 136.61% |
2020 Q4 | 738 Thousand USD | -46.05% |
2020 Q3 | 1.36 Million USD | -53.21% |
2020 Q2 | 2.92 Million USD | 657.51% |
2019 Q1 | 265 Thousand USD | -56.77% |
2019 Q2 | 941 Thousand USD | 255.09% |
2019 FY | 2.28 Million USD | 6.42% |
2019 Q3 | 608 Thousand USD | -35.39% |
2019 Q4 | 475 Thousand USD | -21.88% |
2018 Q4 | 613 Thousand USD | 62.6% |
2018 Q1 | 343 Thousand USD | -53.65% |
2018 Q2 | 818 Thousand USD | 138.48% |
2018 FY | 2.15 Million USD | -73.1% |
2018 Q3 | 377 Thousand USD | -53.91% |
2017 Q1 | 3.1 Million USD | -51.69% |
2017 Q3 | 1.48 Million USD | -44.08% |
2017 Q4 | 740 Thousand USD | -50.24% |
2017 Q2 | 2.65 Million USD | -14.47% |
2017 FY | 7.99 Million USD | -53.94% |
2016 Q2 | 4.53 Million USD | 49.79% |
2016 Q4 | 6.43 Million USD | 91.18% |
2016 Q3 | 3.36 Million USD | -25.71% |
2016 Q1 | 3.02 Million USD | 74.86% |
2016 FY | 17.35 Million USD | -9.89% |
2015 FY | 19.26 Million USD | 269.24% |
2015 Q1 | 181 Thousand USD | -19.91% |
2015 Q4 | 1.73 Million USD | -88.79% |
2015 Q2 | 1.92 Million USD | 962.98% |
2015 Q3 | 15.42 Million USD | 701.87% |
2014 Q3 | 4.82 Million USD | 6695.77% |
2014 Q4 | 226 Thousand USD | -95.32% |
2014 Q2 | 71 Thousand USD | -25.26% |
2014 FY | 5.21 Million USD | -82.32% |
2014 Q1 | 95 Thousand USD | -99.66% |
2013 FY | 29.5 Million USD | 0.0% |
2013 Q1 | 940 Thousand USD | 0.0% |
2013 Q2 | 407 Thousand USD | -56.7% |
2013 Q3 | 548 Thousand USD | 34.64% |
2013 Q4 | 27.6 Million USD | 4937.77% |
Name | Revenue | Revenue Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.885% |
Embecta Corp. | 1.12 Billion USD | 99.942% |
ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.866% |
Dynavax Technologies Corporation | 232.28 Million USD | 99.72% |
Esperion Therapeutics, Inc. | 116.33 Million USD | 99.44% |
Pacira BioSciences, Inc. | 674.97 Million USD | 99.904% |
PainReform Ltd. | - USD | -Infinity% |
Aquestive Therapeutics, Inc. | 50.58 Million USD | 98.713% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 97.298% |
SCYNEXIS, Inc. | 140.14 Million USD | 99.535% |
China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 66.243% |
Cosmos Health Inc. | 53.37 Million USD | 98.78% |
Journey Medical Corporation | 79.18 Million USD | 99.178% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 97.298% |
Safety Shot Inc | 202.67 Thousand USD | -221.212% |
Alpha Teknova, Inc. | 36.68 Million USD | 98.225% |
Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.86% |
Bright Green Corporation | 401.49 Thousand USD | -62.146% |
Procaps Group, S.A. | 409.92 Million USD | 99.841% |
Theratechnologies Inc. | 81.76 Million USD | 99.204% |
Harrow Health, Inc. | 130.19 Million USD | 99.5% |
Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 94.888% |
Biofrontera Inc. | 34.07 Million USD | 98.089% |
DURECT Corporation | 8.54 Million USD | 92.384% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.893% |
Cronos Group Inc. | 88.84 Million USD | 99.267% |
OptiNose, Inc. | 70.98 Million USD | 99.083% |
Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.853% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
RedHill Biopharma Ltd. | 6.51 Million USD | 90.005% |
Organogenesis Holdings Inc. | 433.14 Million USD | 99.85% |
Guardion Health Sciences, Inc. | 12.24 Million USD | 94.685% |
Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 98.354% |
Radius Health, Inc. | 2.88 Billion USD | 99.977% |
Universe Pharmaceuticals INC | 32.3 Million USD | 97.985% |
ProPhase Labs, Inc. | 44.38 Million USD | 98.533% |
Phibro Animal Health Corporation | 1.01 Billion USD | 99.936% |
Procaps Group S.A. | 409.92 Million USD | 99.841% |
Alvotech | 91.43 Million USD | 99.288% |
TherapeuticsMD, Inc. | 1.3 Million USD | 50.0% |
Viatris Inc. | 15.42 Billion USD | 99.996% |
Rockwell Medical, Inc. | 83.61 Million USD | 99.221% |
Aytu BioPharma, Inc. | 81 Million USD | 99.196% |
SIGA Technologies, Inc. | 139.91 Million USD | 99.535% |
Tilray Brands, Inc. | 788.94 Million USD | 99.917% |
Lifecore Biomedical, Inc. | 128.26 Million USD | 99.492% |
Shineco, Inc. | 9.8 Million USD | 93.358% |
PetIQ, Inc. | 1.1 Billion USD | 99.941% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Incannex Healthcare Limited | 12 Thousand USD | -5325.0% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.966% |
Alimera Sciences, Inc. | 80.75 Million USD | 99.194% |
Silver Spike Investment Corp. | 11.72 Million USD | 94.446% |
Assertio Holdings, Inc. | 152.06 Million USD | 99.572% |
Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Petros Pharmaceuticals, Inc. | 5.82 Million USD | 88.819% |
Clever Leaves Holdings Inc. | 17.41 Million USD | 96.262% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | 39.521% |
Avadel Pharmaceuticals plc | 27.96 Million USD | 97.672% |
Hempacco Co., Inc. | 4.04 Million USD | 83.909% |
Alvotech | 91.43 Million USD | 99.288% |
Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 99.794% |
Lantheus Holdings, Inc. | 1.29 Billion USD | 99.95% |
Currenc Group, Inc. | 53.25 Million USD | 98.778% |
Kamada Ltd. | 144.75 Million USD | 99.55% |
Indivior PLC | 1.09 Billion USD | 99.94% |
Evoke Pharma, Inc. | 5.18 Million USD | 87.434% |
Flora Growth Corp. | 76.07 Million USD | 99.144% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | 39.521% |
Evolus, Inc. | 202.08 Million USD | 99.678% |
HUTCHMED (China) Limited | 837.99 Million USD | 99.922% |
Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.899% |
Akanda Corp. | 2.16 Million USD | 69.862% |